back a on and as our that can at this meaningful first ENT the days that progress to beginnings. happy reflect time. confidently in view October is I XXX Looking quarter of now further completed third Intersect I've what my in new I I'm report time and a on progress
taking would sustainable now in success. are XXXX execution in focused on We refining noted remained was financial we consistent time growth the revenue a sound our to communicated strengthening necessary growth ensure quarter as enter expectations return the to and we August. we Our with at performance and precursor driving actions I and the and believe that to that be
our communicated on our priorities the on commitments PROPEL door growth focus access sales with both two, you to SINUVA these while redirecting One, market execution, will partnership. August during we to aligned adding efforts reemphasizing the remain businesses. and Together, open call. as effort; Importantly, our delivering earnings we
of pipeline ASCEND are the in to meaningful this results the drug-coated balloon clinical development received quarter addition, and findings product. the the applying In we study further
of a areas XXXX efforts with walk now on positioning you we through each our I'll how these current us for and see three beyond. focus
PROPEL. addressing issues business, recent of focus by been on a impacted but and has growth the remains bandwidth our product backbone by First, caused SINUVA. family This distraction disproportionate
During our third specific to that three ourselves to on actions PROPEL. in quarter you a to to call, put were restore to we we committed position over deliver time growth going
and development clinical to The adoption. first bridging was by deeper reprioritize growth to drive support to activities market broader our evidence
balance launch. meaningful PROPEL, efforts was supporting our second meaningfully to still the greater bring team's the of to sales a on strengthen The greater SINUVA -- while focus
to we And back could on that that in down striving PROPEL our down the communicated three inventory finally, ASP, quarter. up drive work to while orders often we simultaneously and accumulated pleased discounted addressed inventory points in any channel. successfully third the build you I'm pull tell of larger these intention bulk to all
interactions market physicians activities. and some effort we share have refocusing considerable To with clinical put to into emphasize development our selling specifics,
encourage evidence of PROPEL; use the three, a clinical the PROPEL one, substantial our using to; number all of leveraging means development market indicated in of and sinus extend usage of PROPEL, audience physicians two, patients; sinusitis For areas cavity. expand chronic wider across the
teams sales our across cases. clinical the field held In designed benefits refresh to approach August, message. sinusitis toughest meetings beyond our the country just a back-to-basics with with proven PROPEL's we extend regional
messaging. clarify workshops marketing ensure that building and these and help mastery best sales targeted practice and interactive of During led prioritize our segment, and objectives, leadership physician our skill meetings, universe our
targeted PROPEL and drive to in product and deployment deeper order franchise a by broader was our expert direction to clear selling and The adoption. tailored more prioritize growing clinical
ENT quarter new has helped sales full first managers, approach reimbursement our was seven coordinated SINUVA QX and This greatly of our our core specialist balance, to regional resourced XXX-person salesforce team, team. fully partnership our XX-person our team the Regarding improve of effort. account balance among their
primary selling in SINUVA a to a requirements of the PROPEL drug attend clinical away of Previously, of reimbursement our inherent with demands team from to drawn versus of a new sales care distinct was introducing site a device.
office. skill, resources will drug effort you address whereas ambulatory as introduction. in specialty of primarily This a specific the have our primarily and SINUVA's clinical groups and recall, growth our PROPEL, time the hospital in that that We with classified is classified as field ASC, knowledge, is to core. is focus device smaller reestablish in a is greater and and renewed center, used the SINUVA primary selling with used and PROPEL the can and in now frees come allocation to deliberate clinical reimbursement force needs drive surgical
SINUVA As selling. work the SINUVA our prioritize the regional new account manage SINUVA in demands, proportionately reimbursement driving assist team directors managers of much PROPEL and and sales can
also that continue in and the our measurement tracking we improve and Year. accordingly quarter to efforts compensation New expect strengthen field incentive will this fourth adjust balance as We of into the and
third tightly PROPEL encouraging grown customer us and largely product the quarterly In this issue existing inventory inventory procedure-driven for behind our Finally, where on more year-end. the reducing continue by assessment to we at of believe in consciously we end achieved shelves quarter, beyond shipments shelf goal aligned limited had the utilization to we flow, be will usage. customer of customers order our
clinical efforts we are year are But PROPEL our naturally and this of you order procedure-driven know a and achieve and expect PROPEL point a flowing with both of premature I in of purpose on focus confident market growth to pipeline, proportionate PROPEL. a development ask it's better to that our next conveying indicate with what will we level we sense more more reestablish will focus selling, that hope we Though renewed on growth. we progress. At
we SINUVA, all designed of a adoption. advance to to have product Turning number initiatives coordinated significantly
and access assurance of reimbursement of But patients feedback the strong in We coverage the from key office adoption ease physician clinical of physicians. continue and to product setting. determinant receive remains very
our we discussed And key efforts. exceeded bringing even last and we we in tell committed we happy that to deliverables, these achieved As to the last particularly our our call in pharmacy I'm set to of August. call, partners, in goals support in stronger execution are on you specialty
month, last a we the well access SINUVA. support focused ties in new to both on payers physician specialty Specifically, with added new to pharmacy hub a streamlining physician as national as
J and supporting code wholesaler. also commercial of newly contracting We we are an and the additional issued on use finalizing are payer CMS specialty
we provide as third-party investigation. facilitate me some Since to Let with launch, further have on service physicians hub to benefits a capabilities. these work new referred partners to patient engaged and a background provider
hub patient Our addressed this it to able our understand ConnectiveRx. easier technology-enabled process. basics processing to been to we expect first a faster, the case, In to strengthen making with physicians this partner of authorization more better, for benefits status. have But coverage services translate more hub transparent and technology-enabled we
Our new up and partner running was on Xth. October
and into phase to as analytics the new We these with well through XXXX. operations eye an as services are data as we working start-up enables expand move the the hub
very with journey. Orsini mid-October, chronic fit We specialty specialty Healthcare. to partner throughout exceptional a We care their their is see in on SINUVA as pharmacy providing nationwide also in rhinosinusitis. strong an services new focused added a patients important pharmacy, Orsini
critical about we ingredients We today. are excited offers have partnership been Orsini the two addition missing as
payers. a with array broad of payers has major Orsini including established First, arrangements national
is benefit addition claims product needs medical medical checking pharmacy I number the Orsini benefits look just that they benefit Second, in payer review medical at of SINUVA. processes claims the policies versus on a to and for require mean, patient formulary.
The Orsini to Up specialty medical for via benefit now, the physicians open specialty capabilities benefit a door have to SINUVA required medical receive patients fulfillment through claims buy-and-bill for distributor. pharmacy. at
belt, need physicians purchase the is or when specialty product to seek impact give field you reimbursement very With pharmacy clearly but it's early a only assessment too they buy-and-bill As three not is a reports advantage to of early from are reminder, do the as under full of encouraging. weeks Orsini's required. do the fulfillment that for our
code, in remains specific in a side the specific October this has SINUVA mix on work is Xst. element price. progress of code as the which a assign became to the Another Implementation effective yet J reference CMS JXXXX, Medicare
effective price posted anticipate with this X. We be that are CMS working and will January
we On code of determine estimate Commercial and these that of the their many payers in side, billing where to specific is J SINUVA XX% code payers patients own are positive systems the their The utilize true to are J covered. ease pricing SINUVA. payer for commercial adoption. starting already for a
for J XXXX underscore code specific addition assigned office also the for office is care. the to hospital I'll setting In or PROPEL than reimbursement setting ASC. rather of in in for the coding SINUVA, providing
serve will office. flip use adversely code the physician to are practices on We dollar reimbursement or for J PROPEL coverage PROPEL the with of per the side, to the value in the office in engaged and that broaden of potentially impact payers the assess
is of QX. the scenario treated to this approximately start In XXX of commercialization a now element X% SINUVA basis, business, representing patients been X% since product of an in with approximately metrics On revenue. either XXXX a of with roughly increase patients our small have PROPEL
ordering. XXX Since have in SINUVA, launched with engaged one-third buy-and-bill successfully about XXX physicians patients of which about have treated or
Another to supporting of to XX% continues that SINUVA. SINUVA access lives very with coverage currently for positive grow is having factor approximately payer covered our
physicians code believe is J flows established office. should efficiency and physician in code burden partnered SINUVA the streamline insurance depth and hub The product growth believe the The the Looking pharmacy we with further streamline obtaining at new used. should J consistently once more workload reimbursement use and population. and specialty the our of breadth buy-and-bill a against increasing the while processing being through the able SINUVA reducing to that increase fully broader we ahead, when reimbursement adoption that channel changes confidence in offices will the should ENT stimulate patient pharmacy physician's
is adding we specialty a lot the of And a over to enhancement progress and said, that quarter, by potential. all an of national as So full With additional reach. a look our work by minimum, pharmacy unlock means done. lot we to change at our SINUVA's anticipate next further as a no past spring
In additional our the in to add with support for addition, hospital near a customers. wholesaler term on specialty focus improving we particular clinic intend
With the expansion demand clinical months, we are generation we the place coming effectively our placed in efforts. partnered to patient further put better and infrastructure, in channel ramp up and now have
subject sinus our drug-coated our to come investigational third we now balloon. area, And ASCEND,
disclosed trial was endpoint, of few obstruction. patency completed balloon conventional a against As or our hit ASCEND independent an claim upon weeks a and of based superiority the not did view a ago, accessor's lack primary which we sinus
to unchartered patency the was as conventional measurement novel proved relatively This our for for be challenging grading territory product balloons. endpoint and and of
As XXX(k) governed our stents. PMA and as much as devices conventional study clinical had delivering balloons have NDA not drug
drug-coated our of study endpoint at ASCEND was of comparable Importantly, the all control balloon primary nearly the observed the the looking and performance across data, the of patency. parameters when to at trial least measured relative including
differences showed and statistically In reduction measured addition, balloon mometasone significant secondary positive to our time inflammation meeting polypoid importantly, reduction directly polyps, are including include of statistically and day drug, XX. attributable in at endpoints endpoints important in at all the several physicians to drug-coated edema, These statistically that furoate. significant in points significant
steroid trial of demonstrated oral serious through adverse and our events related in for balloon also the significant drug statistically were We events the observed. no there XX. adverse a ASCEND device-related were component to day reduction Further, the need no in interventions drug-coated
study. of this study serve not earlier that As a kind study, pivotal a its as we might first clear communicated
can drug work clinicians committed our now upon remain We with with patients PMA. if believe submitting their is delivery we'll with the clinical to assessing drug-coated balloon a we closer for very innovation and devices. trial encouraged based studies team role by of further the to chronic localized benefit play But prior results, examination are next of we portfolio Our evidence sinusitis. in to FDA of the needed the steps leading and are determine our
to towards balloon To new of prioritization this, support portfolio to drug-coated the all the clear pathway adding platform evidence access future. PROPEL, a summarize commercial focus SINUVA, physician on and a renewed and capabilities in to
Jeri to and to Now on outlook. turn our financials the let touch me over call
